Donanemab

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 01:40:44 GMT 2025` Edited by `admin` on `Wed Apr 02 01:40:44 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG1
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	1ADB65P1KK
Record Status	`Validated (UNII)`
Record Version

Download

Related Record	Type

Name

Type

Language

LY 3002813

Preferred Name

English

Donanemab

Official Name

English

LY-3002813

Code

English

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS APP (AMYLOID BETA A4 PRECURSOR PROTEIN) A BETA 3-PYROGLUTAMYL PEPTIDES, A.BETA. 3 (3-X)), HUMANIZED MONOCLONAL ANTIBODYGAMMA1 HEAVY CHAIN HUMANIZED (1-444) (VH (HOMO SAPIENS IGHV1-3*01 (84.7%)-(IGHD)-IGHJ4*01 (

Systematic Name

English

DONANEMAB [USAN]

Common Name

English

donanemab [INN]

Common Name

English

Donanemab [WHO-DD]

Common Name

English

Immunoglobulin G1, anti-(human pyroglutamyl A? (3-x) peptide)(human clone LY3002813 ?1-chain), disulfide with human clone LY3002813 ?-chain, dimer

Common Name

English

Code System Code Type Description

CAS

1931944-80-7

Created by admin on Wed Apr 02 01:40:44 GMT 2025 , Edited by admin on Wed Apr 02 01:40:44 GMT 2025

PRIMARY

INN

10922

Created by admin on Wed Apr 02 01:40:44 GMT 2025 , Edited by admin on Wed Apr 02 01:40:44 GMT 2025

PRIMARY

SMS_ID

300000005929

Created by admin on Wed Apr 02 01:40:44 GMT 2025 , Edited by admin on Wed Apr 02 01:40:44 GMT 2025

PRIMARY

WIKIPEDIA

Donanemab

Created by admin on Wed Apr 02 01:40:44 GMT 2025 , Edited by admin on Wed Apr 02 01:40:44 GMT 2025

PRIMARY

USAN

LM-184

Created by admin on Wed Apr 02 01:40:44 GMT 2025 , Edited by admin on Wed Apr 02 01:40:44 GMT 2025

PRIMARY

FDA UNII

1ADB65P1KK

Created by admin on Wed Apr 02 01:40:44 GMT 2025 , Edited by admin on Wed Apr 02 01:40:44 GMT 2025

PRIMARY

NCI_THESAURUS

C166484

Created by admin on Wed Apr 02 01:40:44 GMT 2025 , Edited by admin on Wed Apr 02 01:40:44 GMT 2025

PRIMARY

From	To
1_22	1_96
1_142	1_198
1_259	1_319
1_365	1_423
1_218	3_219
1_224	2_224
1_227	2_227
2_22	2_96
2_142	2_198
2_259	2_319
2_218	4_219
2_365	2_423
3_23	3_93
3_139	3_199
4_23	4_93
4_139	4_199

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_295
N	2_295

Related Record Type Details


					NFZ9GEM9QP

HUMAN .BETA.-AMYLOID PEPTIDE (PGLU3-40)

TARGET->INHIBITOR OF AGGREGATION

Comments:

A?pE is of interest as it has been shown to be one of the dominant forms of A? present in the hippocampi and cortices of patients with Alzheimer's disease. However, arguably of most importance is that A?pE is specifically only found within cerebral A? plaques.2 In-vitro analysis has revealed that A?pE3 shows an increased rate of aggregation up to 250 times that of full-length A?, irrespective of its C terminus.

Amount:


					MA5AQ51HF3

HUMAN .BETA.-AMYLOID PEPTIDE (PGLU3-42)

TARGET->INHIBITOR OF AGGREGATION

Comments:

A?pE is of interest as it has been shown to be one of the dominant forms of A? present in the hippocampi and cortices of patients with Alzheimer's disease. However, arguably of most importance is that A?pE is specifically only found within cerebral A? plaques.2 In-vitro analysis has revealed that A?pE3 shows an increased rate of aggregation up to 250 times that of full-length A?, irrespective of its C terminus.

Amount:

SUB_CONCEPT->SUBSTANCE

Amount:

Related Record Type Details


					1ADB65P1KK

Donanemab

ACTIVE MOIETY

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL